JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

Figure 6

CD8 E percentages in JCV-DNA+ and JCV-DNA− samples, after stratification according to natalizumab infusion number. Comparison of CD8 E percentages between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples for 0: 6.6%   versus 5.1%  , 12: 14.7%   versus 11.1%  , 24: 13.6%   versus 8.0%  , 36: 9.5%   versus 8.1%  , and : 12.5%   versus 6.7%  . Data are shown as median [interquartile range]. Statistical analysis was performed using the 2-tailed Mann–Whitney test (, , , , and , for 0, 12, 24, 36, and , resp.). Lines and whiskers represent median values and interquartile ranges, respectively. CD8 E: CD8 effectors. 0: no infusions, 12: from 1 to 12 infusions, 24: from 13 to 24 infusions, 36: from 25 to 36 infusions, and : over 36 infusions of natalizumab. ; ; ; .